Pyronaridine
- Generic Name
- Pyronaridine
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32ClN5O2
- CAS Number
- 74847-35-1
- Unique Ingredient Identifier
- TD3P7Q3SG6
- Background
Pyronaridine has been investigated for the treatment of Malaria.
- Indication
本品用于治疗脑型、凶险型及耐氯喹虫珠所致的恶性疟，也用于治疗间日疟。
- Associated Conditions
- Acute Falciparum Malaria, Acute Malaria caused by plasmodium vivax
Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)
- Conditions
- Malaria Infection
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 192
- Registration Number
- NCT05974267
- Locations
- 🇧🇫
Groupe de Recherche Action en Sante (GRAS), Ouagadougou 06, Burkina Faso
🇬🇲MRC Unit The Gambia at LSHTM, Banjul, Gambia
🇰🇪Kisumu County Referral Hospital, Kisumu, Kenya
Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)
- Conditions
- Acute Malaria
- Interventions
- Drug: M5717 330 mgDrug: M5717 500 mgDrug: Pyronaridine-artesunate (Pyramax) 360 mg/120 mgDrug: M5717 660 mgDrug: Pyronaridine-artesunate (Pyramax) 720 mg/240 mg
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 38
- Registration Number
- NCT05689047
- Locations
- 🇺🇬
Infectious Diseases Research Collaboration (IDRC), Tororo, Uganda
🇧🇫Groupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso
🇲🇿Centro de Investigação em saúde de Manhiça/Fundação Manhiça (CISM/FM), Maputo, Mozambique
Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults
- Conditions
- Malaria
- Interventions
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 30
- Registration Number
- NCT05441410
Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)
- Interventions
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Armaceutica, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05291390
- Locations
- 🇸🇳
Dalal Jamm Hospital, Guediawaye GOL SUD, Dakar, Senegal
Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria
- Conditions
- Protozoan InfectionsParasitic DiseaseMalaria RecrudescenceMalariaParasitemiaMalaria,Falciparum
- Interventions
- Biological: P. falciparum IBSM infection
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Medicines for Malaria Venture
- Target Recruit Count
- 10
- Registration Number
- NCT05287893
- Locations
- 🇦🇺
South Bank, Brisbane, Queensland, Australia
🇦🇺USC Clinical Trials, Morayfield, Brisbane, Queensland, Australia
A Healthy Volunteer Safety Study of Pyronaridine Tetraphosphate Taken in Combination With Piperaquine Tetraphosphate
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Medicines for Malaria Venture
- Target Recruit Count
- 37
- Registration Number
- NCT05160363
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, London, United Kingdom
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Medicines for Malaria Venture
- Target Recruit Count
- 30
- Registration Number
- NCT04368910
- Locations
- 🇰🇷
Inje University Ilsan Paik Hospital, Goyang-si, Korea, Republic of
🇰🇷Eulji General Hospital, Seoul, Korea, Republic of
Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission
- Conditions
- Malaria,Falciparum
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 100
- Registration Number
- NCT04049916
- Locations
- 🇲🇱
Malaria Research and Training Centre, Bamako, Mali
🇳🇱Radboud university medical center, Nijmegen, Netherlands
Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections
- Conditions
- Malaria,Falciparum
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT03814616
- Locations
- 🇬🇲
MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine,, Fajara,, Banjul,, Gambia
🇿🇲Tropical Diseases Research Centre, Ndola, Zambia
Cohort Event Monitoring Study of Pyramax®
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
- Target Recruit Count
- 8572
- Registration Number
- NCT03201770
- Locations
- 🇬🇦
CERMEL, Albert Schweitzer Hospital, Lambaréné, Gabon
🇨🇲The Biotechnology Center Nkolbisson, Univ of Yaounde I, Messa, Yaoundé, Cameroon
🇨🇮Institut Pierre Richet / Institut National de SanPublique (IPR/INSP), Bouaké, Côte D'Ivoire
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.